Abstract
The data on tryptamine µg/g of body weight (µM ranges of concentrations) and mg/g of tissue from 1997–2020 are summarized in Table 21.1. Table 21.1 includes the data on tryptamine increase following specific diet compounds such as fructooligosaccharides, galactooligosaccharides, pectin, inulin, maize. The µg/mg (1mg/g) concentrations of tryptamine were detected in the colon of neonatal animals. In human, tryptamine-induced changes similar to those produced by LSD-like hallucinogens. A repot of 1961 provides the results on tryptamine lethal doses (LD50) in mice. The LD50 depends on the presence of monoamine oxidase inhibitors (MAOI), The MAOI iproniazid, nialamide, isocarboxazid, phenelzine, pheniprazine, and tranylcypromine potentiated tryptamine action with increased mortality. MAOI tranylcypromine is in use as antidepressant. Subchronic treatment of human volunteers with the weekly increasing doses of MAOI tranylcypromine (dosage 20mg/day during a week) resulted in elevation of urinary tryptamine up to 720% compared to control. MAOI combined with uncontrolled variable tryptamine can be a cause of sudden death in humans.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
